Press Releases July 29, 2026 04:15 PM

Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call

Spectral AI Announces Date for Q2 2026 Financial Results and Conference Call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
MDAI

Spectral AI, Inc., a Dallas-based AI company specializing in medical diagnostics for wound care, will report its second quarter financial results on August 11, 2026. The company will also host a conference call to discuss these results, focusing on its DeepView System designed to improve wound treatment outcomes.

Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
MDAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Spectral AI focuses on AI-driven medical diagnostics to enhance treatment decisions in wound care, including burns.
  • The DeepView System provides predictive diagnostics to facilitate faster and more accurate wound assessments, aiming to improve patient outcomes and reduce healthcare costs.
  • The company is publicly traded on the Nasdaq under the ticker MDAI and will announce Q2 2026 financial results on August 11, 2026.

DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.

Investors interested in participating in the live call can dial into the conference call as follows:

  • 833-890-6620 – U.S.
  • 412-564-3789 – International

In addition, a simultaneous webcast of the financial results call may be accessed online from the Events section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.

Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Investors:
The Equity Group
 Devin Sullivan
Managing Director
[email protected]
Conor Rodriguez
Associate
[email protected]  



Risks

  • Forward-looking statements include uncertainties that could cause actual results to differ materially, such as market acceptance, regulatory approvals, and execution risks.
  • Risks detailed in the company’s SEC filings could affect financial performance and business operations.
  • Technological adoption in healthcare often faces reimbursement and integration challenges that could impact growth.

More from Press Releases

Baker Hughes and Venture Global Advance Next Phase of U.S. Gas Infrastructure Growth Sep 13, 2026 Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026